More importantly, highly glycan-specific anti-STn antibodies conjugated to the cytotoxic drug monomethyl auristatin E (MMAE) as developed in Prendergast et. al, [25] decreased both OvCa cell viability in vitro and OvCa xenograft tumor volume in vivo, supporting our hypothesis that targeting of STn in ovarian tumors may be an effective clinical strategy. This evidence concerns the gene EEF1A2 and ovarian neoplasm.